Quantcast

Latest Neuroblastoma Stories

2010-06-15 00:59:03

CHOP oncology chief working to translate his lab's genetic findings into treatments Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge"”much of it based on efforts by Maris and his colleagues at The Children's Hospital of...

2010-06-14 10:25:00

--CHOP Oncology Chief Working to Translate His Lab's Genetic Findings into Treatments-- PHILADELPHIA, June 14 /PRNewswire-USNewswire/ -- Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge--much of it based on efforts by Maris...

2010-06-09 10:01:00

--In Colket Building, Scientists Will Translate Research into Real-Life Treatments for Children -- PHILADELPHIA, June 9 /PRNewswire-USNewswire/ -- The Children's Hospital of Philadelphia will dedicate its new Ruth and Tristram Colket, Jr. Translational Research Building on Wednesday, June 9, at 11 a.m. Launched with an initial gift of $25 million from Ruth M. and Tristram C. Colket, Jr., the 12-story, environmentally friendly structure houses high-profile, cutting-edge programs for...

2010-06-07 07:35:00

Perifosine demonstrated to be safe and tolerable, with early signs of clinical benefit in advanced refractory pediatric neuroblastoma patients QUEBEC CITY, June 7 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company") a late-stage drug development company specialized in oncology and endocrine therapy, today announced that Phase 1 data of perifosine (KRX-0401) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster...

2010-06-07 07:30:00

NEW YORK, June 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 1 data of KRX-0401 (perifosine) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, IL. Perifosine is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation...

2010-06-05 09:30:00

CHICAGO, June 5 /PRNewswire/ -- Researchers from St. Jude Children's Research Hospital and the Pediatric Brain Tumor Consortium (PBTC) presented today at the American Society of Clinical Oncology the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor. The research focused on a new way to attack the tumors by blocking the Hedgehog pathway that is linked to approximately 20 percent of medulloblastomas. The study is the...

2010-05-17 07:35:00

Perifosine observed to be an effective novel agent in neuroblastoma cells in vitro and in vivo Phase 1 data of single agent perifosine as a treatment for recurrent solid tumors in pediatric patients, including neuroblastoma patients, to be presented at ASCO QUEBEC CITY, May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced publication of an article...

2010-05-17 07:30:00

NEW YORK, May 17 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced the publication of an article in the May 12th Journal of the National Cancer Institute, entitled "In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine," demonstrating the single agent activity of KRX-0401 (perifosine) in neuroblastoma tumor preclinical models. Neuroblastoma is the most common pediatric solid tumor. Perifosine, the Company's novel,...

2010-05-10 09:45:04

A multicenter trial led by investigators from St. Jude Children's Research Hospital achieved 71 percent survival after three years"”20 percent better than previously reported US rates More individualized therapy and better supportive care helped push the survival for children with acute myeloid leukemia (AML) to 71 percent three years after diagnosis, according to new research led by St. Jude Children's Research Hospital investigators and reported in the medical journal The Lancet...

2010-04-20 07:35:00

QUEBEC CITY, April 20 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that preclinical data in neuroblastoma for perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, will be presented at the 101st Annual Meeting of the American Association for...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related